SCHEMBL25788653

SCHEMBL25788653

COCCn1nnc(-c2ccc(C)cc2Nc2ccc(C(C)(F)P)cc2)n1

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ABCG2 Q9UNQ0 6/20 0.35
▸ LMNA P02545 3/20 0.35
▸ SMN1; SMN2 Q16637 3/20 0.35
▸ ALDH1A1 P00352 5/20 0.34
▸ MAPT P10636 3/20 0.34
▸ KMT2A Q03164 2/20 0.34
▸ KDM4E B2RXH2 2/20 0.34
▸ HPGD P15428 2/20 0.34
▸ HTT P42858 1/20 0.34
▸ RAB9A P51151 1/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ HSD17B10 Q99714 1/20 0.34
▸ KDR P35968 1/20 0.33
▸ FLT3 P36888 1/20 0.33
▸ USP2 O75604 1/20 0.33
▸ TP53 P04637 1/20 0.33
▸ ABCB1 P08183 2/20 0.33
▸ TSHR P16473 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25787793 0.88 ALDH1A1 (0.37) ABCG2LMNASMN1; SMN2ALDH1A1MAPT
SCHEMBL25787720 0.81 KMT2A (0.42) ABCG2LMNASMN1; SMN2ALDH1A1MAPT
SCHEMBL20552408 0.81 ABCG2 (0.42) ABCG2LMNASMN1; SMN2ALDH1A1MAPT
SCHEMBL20552459 0.80 ABCG2 (0.47) ABCG2LMNASMN1; SMN2ALDH1A1MAPT
SCHEMBL25787850 0.79 GUCY1B2 (0.38) LMNASMN1; SMN2ALDH1A1MAPTKMT2A
SCHEMBL25787722 0.78 ABCG2 (0.42) ABCG2LMNASMN1; SMN2ALDH1A1MAPT
SCHEMBL25787764 0.74 LMNA (0.42) ABCG2LMNASMN1; SMN2MAPTKMT2A
SCHEMBL21749242 0.73 TP53 (0.44) ABCG2LMNASMN1; SMN2ALDH1A1MAPT
SCHEMBL25787803 0.73 USP2 (0.46) ABCG2LMNASMN1; SMN2ALDH1A1MAPT
SCHEMBL20553430 0.73 MAPT (0.41) ABCG2LMNASMN1; SMN2ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230192607-A1 TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-06-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230192607-A1 TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF TEAD1, TEAD4, TEAD2 ABCG2 2217/4885LMNA 2451/4885SMN1; SMN2 3035/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback